Document is current
Any future updates will be listed below
-
Authors
Dao, Tao
Klatt, Martin G.
Korontsvit, Tatyana
Mun, Sung Soo
Guzman, Sean
Mattar, Marissa
Zivanovic, Oliver
Kyi, Chrisann K.
Socci, Nicholas D.
O’Cearbhaill, Roisin E. https://orcid.org/0000-0001-8217-4554
Scheinberg, David A.
-
Funding
Funding for this research was provided by:
National Cancer Institute (P30 CA008748, CA55349, CA23766)
- License Information
-
More Information
Article History
Received: 24 July 2020
Accepted: 15 October 2020
First Online: 29 October 2020
Compliance with ethical standards
:
: David Scheinberg is on the advisory board of, has received consulting fees from, and/or has equity in Progenics Pharmaceuticals, Sellas, KLUS, Iovance Biotherapeutics, Inc., Pfizer, Actinium Pharmaceuticals, Inc., OncoPep, and Eureka Therapeutics. Tao Dao has equity in Eureka Therapeutics. Dr O'Cearbhaill's institution receives funding for clinical research that she is leading from Celgene/Juno, Tesaro/GSK, Ludwig Cancer Institute, Abbvie, Regeneron, TCR2 Therapeutics, Atara Biotherapeutics, MarkerTherapeutics, Syndax Pharmaceuticals, Genmab Therapeutics, Sellas Therapeutics, Genentech, Kite Pharma, and the Gynecologic Oncology Foundation. Dr O’Cearbhaill has served on a once-off advisory board for Regeneron, Genmab Therapeutics, and GSK. All other authors declare no conflict or competing interests.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the Memorial Sloan Kettering Cancer Center Institutional Review Board (IRB Human Subject Assurance Number FW00004998) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
